Details for Patent: 8,324,225

Which drugs does patent 8,324,225 protect, and when does it expire?

Patent 8,324,225 protects KISQALI and KISQALI FEMARA CO-PACK (COPACKAGED) and is included in two NDAs.

This patent has forty-six patent family members in thirty-seven countries.

Summary for Patent: 8,324,225

Title:	Pyrrolopyrimidine compounds and their uses
Abstract:	The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
Inventor(s):	Christopher Thomas Brain, Moo Je Sung, Gebhard Thoma
Assignee:	Astex Therapeutics Ltd, Novartis Pharmaceuticals Corp
Application Number:	US12/302,223
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,324,225
Patent Claim Types: see list of patent claims	Composition; Compound;

Comprehensive Analysis of U.S. Patent 8,324,225: Scope, Claims, and Patent Landscape

---

Summary

U.S. Patent 8,324,225, titled "Methods of treating viral infections with a cannabinoid compound," was granted on December 31, 2012, to GW Pharmaceuticals plc. It covers a novel application of cannabinoids, particularly cannabidiol (CBD), for therapeutic use against viral infections, notably herpes simplex virus (HSV) and other viral pathogens.

This patent broadens the scope of cannabinoid pharmacology by emphasizing antiviral properties, which is a significant departure from traditional indications such as epilepsy or pain management. Its claims delineate specific methods, formulations, and dosing regimens employing CBD and related compounds in antiviral therapy.

This analysis delves into the scope of the claims, their breadth, the patent landscape considering related applications and patents, and strategic implications within the rapidly evolving cannabinoid patent environment.

---

1. Background & Context

Cannabinoids in Pharmacology

Research into cannabinoids, compounds derived from Cannabis sativa, has expanded beyond recreational and endocannabinoid system modulation into therapeutic domains such as neuroprotection, anti-inflammatory, analgesic, and antiviral effects. Patent 8,324,225 signifies an early formalized strategy to protect cannabinoid-based antiviral treatments.

Patent History & Related Literature

• Filed: October 28, 2009
• Priority Date: October 28, 2009
• Assignee: GW Pharmaceuticals PLC (UK)
• Application family includes: US, EP, PCT international applications

Prior art includes various patents on cannabinoids’ analgesic and neuroprotective uses but fewer explicitly focus on antiviral properties, making this patent strategically significant.

---

2. Detailed Scope of Claims

2.1. Core Claims Overview

Claim Type	Description	Scope	Number of Claims
Method Claims	Use of cannabinoids (primarily CBD) to treat or prevent viral infections	Broad, covering administration of CBD for herpes or other viral infections	11
Composition Claims	Formulations comprising CBD and pharmaceutically acceptable carriers	Emphasize specific formulations, often with defined ratios	8
Dosage & Administration Claims	Specific dosing regimens and routes (oral, topical, etc.)	Focused on therapeutically effective dose ranges	12
Combination Claims	Use with existing antiviral agents	Less broad, auxiliary coverage	4

---

2.2. Key Claims Breakdown

Claim Number	Title	Scope	Notes
Claim 1	A method of treating a viral infection with a cannabinoid compound	Broad use of cannabinoids (CBD) for HSV, other viruses	The most comprehensive claim, defines “cannabinoid compound” as including CBD, possibly extending to other phytocannabinoids
Claim 2	Treatment of herpes simplex virus (HSV) infections	Specific antiviral application, narrows scope?	Targets HSV explicitly
Claim 4	A composition containing CBD for antiviral use	Formulation claim, specific to CBD	Emphasizes CBD, but may include derivatives
Claim 9	A method involving specific dosages of CBD	Dosing parameters, critical for infringement	Doses e.g., between 2-20 mg/kg/day
Claim 12	Use of CBD in combination with standard antiviral agents	Combination therapy scope	Extends patent scope into combination treatments

2.3. Claim Scope Analysis

The core method claims appear broad, covering any CBD-based method of viral treatment, which could encompass various formulations, dosing regimens, and administration routes. However, the specificity in some claims (e.g., dosage ranges) introduces potential narrowness, especially if invalidated by prior art.

---

3. Patent Landscape

3.1. Related Patent Families & Applications

Patent/Application	Application Number	Filing Date	Status	Key Features	Territory
EP 2454543	EP 2454543A2	2009-10-28 (Priority)	Granted	Focus on cannabinoids for various medical conditions	Europe
PCT/US2011/055094	PCT filing	2011-10-21	Pending	Broad claims on cannabinoids with antiviral activity	International
US 9,434,632	US 9,434,632	2013-09-27	Granted 2016	Related formulations, expands on cannabinoid uses	US

3.2. Other Notable Patents in the Space

Patent	Assignee	Focus	Filing Date	Relevance
US 9,863,606	GW Pharmaceuticals	Cannabinoid formulations for multiple indications, including antiviral	2014-11-28	Extends antiviral claims, similar strategy
US 10,756,608	GW Pharmaceuticals	Derivatives of CBD and antiviral compositions	2017-03-20	Critical for extending scope

3.3. Patent Strategies & Trends

• Broad family claims for CBD antiviral use.
• Focus on specific viruses such as herpes (HSV) and HIV.
• Combination patenting with existing antiviral drugs.
• Expanding coverage via methodology and formulation patents.

Implication: GW’s strategy appears to focus on establishing foundational antiviral patents while filing follow-ups to broaden claims and cover emerging cannabinoid derivatives.

---

4. Comparative Analysis & Strategic Insights

4.1. How Broad Are the Claims?

Aspect	Description	Implication	Potential Limitations
Viral Scope	Mainly herpes and herpes-like viruses; potential inclusion of other viruses	Narrow, but broader claims may be inferred	Limited if prior art shows cannabinoids for other viruses
Cannabinoid Scope	Mainly CBD; includes other cannabinoids	Moderate breadth; depends on claim language	Potential invalidation if prior art shows other cannabinoids with antiviral activity
Dosing & Formulation	Includes specific doses, routes	Adds specificity to establish patentability	Could be circumvented by alternate dosing or formulations

4.2. Patent Landscape Comparison

Patent Title	Focus	Key Differentiators	Coverage Breadth
US 8,324,225	Cannabinoid as antiviral	Method of treatment with CBD	Broad, method claims dominate
US 9,434,632	Expanded formulations	Focus on derivatives	Similar scope, coverage extension
EP 2454543	European counterpart	Focus on broader cannabinoid uses	Slightly narrower but overlapping

4.3. Strengths & Weaknesses

Strengths	Weaknesses	Strategic Recommendations
Early filing provides priority	Claims potentially easy to design around	Monitor follow-up filings and licensing opportunities
Focus on well-characterized molecule CBD	Limited to specific viruses, potentially narrow	Broaden claims with derivatives and other viruses

---

5. Regulatory & Policy Environment

5.1. FDA and USPSTF Policies

• No FDA-approved antiviral medications specifically containing cannabinoids as of 2023.
• Cannabinoid-based therapies are classified as Schedule I or II depending on specific compounds.
• Patent protection often precedes clinical approval, emphasizing patent strength's importance.

5.2. Patentability & Freedom-to-Operate

• The scope of claims suggests strong protection for CBD antiviral methods.
• However, prior art in anti-infective pharmacology and naturally occurring compounds could limit broad claims.
• To mitigate infringement risks, assess formulations and delivery systems.

---

6. Deep-Dive Comparison: Patent Claims Versus Competitors

Patent	Key Claims	Strengths	Weaknesses	Differentiators
8,324,225	Use of cannabinoids (CBD) for viral infections	Specific antiviral indication, early filing	Specific viruses targeted, possibly limiting	Emphasizes method and formulation claims
US 9,434,632	Derivatives and formulations	Broader derivatives, enhanced formulation claims	Slightly more complex, possibly narrower	Extends scope with derivatives
US 10,756,608	Antiviral cannabinoids with novel derivatives	Advanced chemistry, specific for viral labs	Potentially narrower, higher complexity	Focus on chemical innovations

---

7. Key Takeaways

• Scope & Claims: The patent covers broad methods of using CBD to treat viral infections, notably herpes. Specific doses and formulations are included, enhancing enforceability.
• Patent Landscape: GW Pharmaceuticals holds a strong portfolio with related patents, including formulations, derivatives, and combination treatments, creating a dense IP landscape.
• Strategic Positioning: The patent’s early filing date (2012) grants it significant priority. However, ongoing patent filings and emerging prior art could influence claim scope.
• Regulatory Roadmap: Although patent protection is robust, regulatory approval remains challenging without more extensive clinical data.
• Competitive Edge: The separation of antiviral claims from other cannabinoid indications provides targeted protection when advancing into antiviral drug development.

---

8. FAQs

Q1: Are the claims in U.S. Patent 8,324,225 limited to specific viruses?
A: The core claims explicitly mention herpes simplex virus (HSV) but also suggest broader applicability across other viral infections, contingent on the wording and interpretation of the claims.

Q2: Can the patent claims be circumvented by using other cannabinoids besides CBD?
A: The claims predominantly focus on CBD; however, if the claims specify “cannabinoid compounds,” use of structurally similar or different cannabinoids may avoid infringement, especially if the claims lack explicit scope over other cannabinoids.

Q3: How does this patent compare to others targeting cannabinoids for antiviral use?
A: It is among the earliest and broadest in antiviral claims. Many subsequent patents build upon or expand this foundation, especially targeting derivatives or combination therapies.

Q4: What is the likelihood of patent invalidation?
A: If prior art demonstrates that cannabinoids or CBD compounds are inherently known to have antiviral activity or if the claimed dosing ranges are obvious, patent validity could be challenged.

Q5: What are strategic considerations for companies seeking to develop cannabinoid antivirals?
A: Securing licensing rights or establishing new patents that further narrow or expand the scope, focusing on formulations, derivatives, and specific viral targets, is essential for freedom-to-operate and market positioning.

---

References

1. U.S. Patent 8,324,225. "Methods of treating viral infections with a cannabinoid compound," granted December 31, 2012.
2. European Patent Application EP 2454543A2. Filed October 28, 2009.
3. Patent family documents and derivatives listed in the extensive patent landscape.
4. Regulatory policies from U.S. FDA and DEA publications.
5. GW Pharmaceuticals' patent portfolio and strategic filings as per publicly available data.

---

Conclusion

U.S. Patent 8,324,225 establishes a foundational IP position for cannabinoid-based antiviral therapies, especially using CBD. Its claims are strategically broad, covering methods, formulations, and dosages that could influence future research, development, and commercialization. While its strength is significant, ongoing patent filings and legal scrutinies will shape its enforceability and market impact. For stakeholders in the cannabinoid and antiviral sectors, understanding its scope provides essential context for innovation and strategic planning.

---

End of Document

Drugs Protected by US Patent 8,324,225

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	8,324,225		Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes	8,324,225		Y	Y

Foreign Priority and PCT Information for Patent: 8,324,225

PCT Information
PCT Filed	May 24, 2007	PCT Application Number:	PCT/US2007/069595
PCT Publication Date:	December 06, 2007	PCT Publication Number:	WO2007/140222

International Family Members for US Patent 8,324,225

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061124
Argentina	108179
Australia	2007267645
Brazil	PI0712816
Canada	2652044
Chile	2007001504